What is KeyCorp's Forecast for Exagen Q3 Earnings?

Key Points

• KeyCorp analysts predict Exagen will report Q3 2025 earnings of ($0.13) per share, maintaining an "Overweight" rating with a $12.00 target price.
• Recently, other analysts including UBS Group and BTIG Research have also reaffirmed buy ratings on Exagen, reflecting positive sentiment among investment analysts.
• Exagen has shown financial volatility, reporting a negative net margin of 28.85% and a negative return on equity of 130.38% in its latest earnings announcement.

Exagen Inc. (NASDAQ:XGN - Free Report) - Analysts at KeyCorp issued their Q3 2025 earnings estimates for Exagen in a report released on Tuesday, July 29th. KeyCorp analyst P. Knight anticipates that the company will earn ($0.13) per share for the quarter. KeyCorp currently has a "Overweight" rating and a $12.00 target price on the stock. The consensus estimate for Exagen's current full-year earnings is ($0.88) per share. KeyCorp also issued estimates for Exagen's Q4 2025 earnings at ($0.10) EPS and FY2025 earnings at ($0.60) EPS.

A number of other analysts also recently issued reports on XGN. UBS Group reissued an "overweight" rating on shares of Exagen in a report on Thursday, May 15th. BTIG Research reissued a "buy" rating on shares of Exagen in a report on Wednesday, May 7th. Cantor Fitzgerald reissued an "overweight" rating and set a $10.00 price target on shares of Exagen in a report on Wednesday. Canaccord Genuity Group increased their price target on shares of Exagen from $8.00 to $11.00 and gave the stock a "buy" rating in a report on Wednesday. Finally, Craig Hallum initiated coverage on shares of Exagen in a research report on Wednesday, July 23rd. They set a "buy" rating and a $12.00 price objective for the company. Seven investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has an average rating of "Buy" and an average target price of $11.25.

Exagen Stock Performance

Shares of NASDAQ XGN opened at $8.40 on Friday. The company's fifty day moving average price is $7.15 and its 200 day moving average price is $5.39. Exagen has a 1 year low of $1.78 and a 1 year high of $9.10. The company has a market capitalization of $184.80 million, a PE ratio of -9.44 and a beta of 1.58. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.32 and a current ratio of 4.95.

Exagen (NASDAQ:XGN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported ($0.18) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.18). Exagen had a negative net margin of 28.85% and a negative return on equity of 130.38%. The firm had revenue of $17.20 million for the quarter, compared to the consensus estimate of $16.25 million.

Hedge Funds Weigh In On Exagen

A number of large investors have recently added to or reduced their stakes in XGN. Acadian Asset Management LLC acquired a new position in Exagen during the first quarter worth $25,000. Corient Private Wealth LLC purchased a new stake in shares of Exagen during the fourth quarter worth $45,000. Marshall Wace LLP purchased a new stake in shares of Exagen during the fourth quarter worth $66,000. Northern Trust Corp grew its holdings in shares of Exagen by 16.7% during the fourth quarter. Northern Trust Corp now owns 18,375 shares of the company's stock worth $75,000 after buying an additional 2,630 shares in the last quarter. Finally, Huntleigh Advisors Inc. grew its holdings in shares of Exagen by 16.8% during the first quarter. Huntleigh Advisors Inc. now owns 83,108 shares of the company's stock worth $298,000 after buying an additional 11,939 shares in the last quarter. 75.25% of the stock is currently owned by institutional investors and hedge funds.

About Exagen

Exagen Inc develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.